ipilimumab,nivolumab
bms
['ipi/', 'nivo', 'melanoma']
#melanoma orals #asco22 :
neodjuvant ipi/nivo with interim path assessment showed that surgery and further adjuvant therapy could be safely omitted for patients with complete pcr! not the case for patients with partial or no path response: surgery and adjuvant still recommended! 
Hematology and Medical Oncology fellow at Duke University, Lebanese, husband to the best anesthesiologist, IO fan, trialist and skin cancer specialist to be!